At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 222 enrolled
Drug / intervention
YKP3089 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
In Brief
A Phase 2 clinical trial evaluating YKP3089 and Placebo for Partial Epilepsy. Completed, enrolled 222 participants across 38 sites in 4 countries.
Detailed Summary
This study is to evaluate the efficacy of YKP3089 in reducing seizure frequency when compared to baseline in subjects with partial onset seizures not fully controlled despite their treatment with 1 to 3 concomitant anti-epileptic drugs. Also to evaluate the safety and tolerability of YKP3089.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPartial Epilepsy
CountriesIndia, Poland, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionJun 2013
Study CompletionJan 2021
TodayJul 2026
First PostedJul 20, 2011
Enrollment StartJul 6, 2011
Primary CompletionJun 1, 2013
Study CompletionJan 28, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.0 years ago
Interventions
YKP3089drug
Capsule, dose to be titrated Tablet, dose to be titrated
Placebodrug
Placebo capsule Placebo tablet